- Zacks•14 hours ago
Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.
- Investor's Business Daily•15 hours ago
The FDA's approval of a multiple sclerosis drug from Roche is likely to be bittersweet for Biogen, analysts said Wednesday.
- Motley Fool•19 hours ago
Confidence in PacBio's differentiated genome sequencing kit continues to build after the thrashing its stock took in December.
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||31.92 - 32.17|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.27|
|Dividend & Yield||1.02 (3.18%)|
|1y Target Est||N/A|